1[1]Prakash A, Markham A. Oral delayed-release mesalazine: a review of itsuse in ulcerative colitis and Crohn＇s disease. Drugs, 1999, 57 (3): 383-408.
2[2]GreenbergGR, FeaganBG, MartinF, etal. Oral budeaonide for active Crohn＇s disease. Canadian inflammatory bowel disease study group. N Engl J Med, 1994, 331 (13): 836-841.
3[3]Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. US Budesonide enema study group. Gastroenterology, 1998, 115(3): 525-532.
4[4]Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn＇s disease. Gut, 1995, 37 (5):674-678.
5[5]Hawthorne AB, Log, an RF,Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J, 1992, 305(6844): 20-22.
6[6]Connel WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet, 1994, 343(8908): 1249-1252.
7[7]Lichtger S, Present DH, Kombluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med, 1994, 330(26):1841-1845.
8[8]Sandbom WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. InflammBowelDis, 1995,1 (1): 48-63.
9[9]Fickert P, Hinterleitner TA, Wenzl HH, et al. Mycophenolate mofetil in patientswithCrohn＇s disease. AmJ Gastroenterol, 1998, 93 (12): 2529-2532.
10[10]Neurath MF, WanitschkeR, Peters M, et al. Randomisedtrialofmycophenolate mofetil versus azathioprine for treatment of chronic active Crohn＇s disease. Gut, 1999, 44 (5):625-628.
